Beth Hecht is a Managing Director and Chief Legal and Administrative Officer and a member of the Investment Committee for Auven Therapeutics, a global private equity firm focused on the biotechnology and pharmaceutical industries with offices in the United States, Switzerland, U.K., Bermuda and the U.S. Virgin Islands. Beth is also a member of the Board of Directors of Neos Therapeutics (NASDAQ: NEOS) where she chairs the Nominating and Governance Committee. She is a graduate of Amherst College and Harvard Law School and started her career as an attorney specializing in intellectual property and corporate transactions at Willkie Farr & Gallagher (NY) and then Kirkland & Ellis (NY). After leaving private law practice, she began her career as a corporate executive and chief legal officer. Beth led the legal, security and regulatory compliance departments and served as a member of the executive committees at both publicly traded and privately held companies in the pharmaceutical and consumer product industries. Before joining Auven she was the Executive Vice President & General Counsel of Sun Products, a $2B consumer products company. Prior to Sun Products she was the Executive Vice President, General Counsel and Corporate Secretary of MedPointe Inc. (formerly known as Carter-Wallace Inc.) a private equity backed pharmaceutical company. Prior to MedPointe, Beth was the Senior Vice President, General Counsel and Corporate Secretary at Warner Chilcott PLC, a NASDAQ listed company specializing in women’s healthcare and dermatology medicines. Before joining Warner Chilcott, she was Vice President, General Counsel and Corporate Secretary of ChiRex Ltd., a NASDAQ listed drug development company. Prior to Warner Chilcott, Beth established the legal function at Alpharma Inc., a NYSE listed multinational company manufacturing and marketing branded and private label pharmaceutical products.